More than a new name: Updates in the management of Clostridioides difficile infection.
Journal
The Nurse practitioner
ISSN: 1538-8662
Titre abrégé: Nurse Pract
Pays: United States
ID NLM: 7603663
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
ppublish
Résumé
Infections from Clostridioides difficile (often called C. diff) have long presented challenges for both patients and clinicians. Traditionally, C. diff has been considered a nosocomial infection, but in recent years, a noticeable spike in community-acquired cases has occurred. C. diff infection (CDI) testing is often complicated, as various testing options with differing sensitivity and specificity for active infection are available. Also, recent guideline changes have altered the recommended treatment of infection. This article discusses recent changes to both the diagnosis and management of CDI and how they can be applied to everyday NP practice.
Identifiants
pubmed: 39049147
doi: 10.1097/01.NPR.0000000000000209
pii: 00006205-202408000-00004
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14-19Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Feuerstadt P, Theriault N, Tillotson G. The burden of CDI in the United States: a multifactorial challenge. BMC Infect Dis. 2023;23(1):132. doi:10.1186/s12879-023-08096-0.
Magill SS, O'Leary E, Janelle SJ, et al. Changes in prevalence of health care-associated infections in U.S. hospitals. N Engl J Med. 2018;379(18):1732–1744. doi:10.1056/NEJMoa1801550.
Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections [published correction appears in Am J Gastroenterol. 2022;117(2):358]. Am J Gastroenterol. 2021;116(6):1124–1147. doi:10.14309/ajg.0000000000001278.
Centers for Disease Control and Prevention. C. diff (Clostridioides difficile). www.cdc.gov/cdiff/index.html. Accessed February 29, 2023.
Abad CLR, Safdar N. A review of Clostridioides difficile infection and antibiotic-associated diarrhea. Gastroenterol Clin North Am. 2021;50(2):323–340. doi:10.1016/j.gtc.2021.02.010.
Ofori E, Ramai D, Dhawan M, Mustafa F, Gasperino J, Reddy M. Community-acquired Clostridium difficile: epidemiology, ribotype, risk factors, hospital and intensive care unit outcomes, and current and emerging therapies. J Hosp Infect. 2018;99(4):436–442. doi:10.1016/j.jhin.2018.01.015.
Guh AY, Mu Y, Winston LG, et al. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med. 2020;382(14):1320–1330. doi:10.1056/NEJMoa1910215.
Giacobbe DR, Dettori S, Di Bella S, et al. Bezlotoxumab for preventing recurrent Clostridioides difficile infection: a narrative review from pathophysiology to clinical studies. Infect Dis Ther. 2020;9(3):481–494. doi:10.1007/s40121-020-00314-5.
Thandavaram A, Channar A, Purohit A, et al. The efficacy of bezlotoxumab in the prevention of recurrent Clostridium difficile: a systematic review. Cureus. 2022;14(8):e27979. doi:10.7759/cureus.27979.
McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):987–994. doi:10.1093/cid/ciy149.
Schwiebert R, Sandoe J. Is there a role of penicillin allergy in developing Clostridioides difficile infection. Curr Opin Gastroenterol. 2021;37(1):1–3. doi:10.1097/MOG.0000000000000690.
Bainum TB, Reveles KR, Hall RG 2nd, Cornell K, Alvarez CA. Controversies in the prevention and treatment of Clostridioides difficile infection in adults: a narrative review. Microorganisms. 2023;11(2):387. doi:10.3390/microorganisms11020387.
Czepiel J, Dróżdż M, Pituch H, et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis. 2019;38(7):1211–1221. doi:10.1007/s10096-019-03539-6.
Rao K, Malani PN. Diagnosis and treatment of Clostridioides (Clostridium) difficile infection in adults in 2020. JAMA. 2020;323(14):1403–1404. doi:10.1001/jama.2019.3849.
Bassi R, Prakash P, Oyetoran A, Elsadek R, Loseke I, Leibach JR. A review on Clostridioides difficile testing and how to approach patients with multiple negative tests: a case report. Cureus. 2023;15(1):e34285. doi:10.7759/cureus.34285.
Lee HS, Plechot K, Gohil S, Le J. Clostridium difficile: diagnosis and the consequence of over diagnosis. Infect Dis Ther. 2021;10(2):687–697. doi:10.1007/s40121-021-00417-7.
Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029–e1044. doi:10.1093/cid/ciab549.
Al Momani LA, Abughanimeh O, Boonpheng B, Gabriel JG, Young M. Fidaxomicin vs vancomycin for the treatment of a first episode of Clostridium Difficile infection: a meta-analysis and systematic review. Cureus. 2018;10(6):e2778. doi:10.7759/cureus.2778.
Cheng Y-W, Fischer M. Fecal microbiota transplantation. Clin Colon Rectal Surg. 2023;36(2):151–156. doi:10.1055/s-0043–1760865.
Bishop EJ, Tiruvoipati R. Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines. J Antimicrob Chemother. 2022;78(1):21–30. doi:10.1093/jac/dkac404.
Kassam Z, Dubois N, Ramakrishna B, et al. Donor screening for fecal microbiota transplantation. N Engl J Med. 2019;381(21):2070–2072. doi:10.1056/NEJMc1913670.
Gerding DN, Kelly CP, Rahav G, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection in patients at increased risk for recurrence. Clin Infect Dis. 2018;67(5):649–656. doi:10.1093/cid/ciy171.